Mustang Bio, Inc., a Fortress Biotech, Inc. company developing immunotherapies based on chimeric antigen receptor engineered T cell (CAR T) technology, has entered into a lease agreement with the UMass Medicine Science Park in Worcester, MA, for a manufacturing facility to support the clinical development and commercialization of its CAR T product candidates.  The facility is expected to be operational for the production of personalized CAR T therapies in 2018. Mustang anticipates initially b...